A clinical-grade automated platform for the manufacturing of CAR-γδ T cells for immunotherapy - Summary - MDSpire

A clinical-grade automated platform for the manufacturing of CAR-γδ T cells for immunotherapy

  • By

  • Jan Kuska

  • Julia Kostyra

  • Lorraine Pinot

  • Evgeny Egorov

  • Nojan Jelveh

  • Lilian A. Martinez Carrera

  • Congcong Zhang

  • Svetlana Khorkova

  • Mario Assenmacher

  • Rimas Orentas

  • Sabine Mueller

  • José Villacorta Hidalgo

  • May 22, 2026

  • 0 min

Share

Objective:

To describe an automated and efficient process for the expansion of Vγ9Vδ2 T cells and the manufacturing of CAR γδ T cells using the CliniMACS Prodigy closed system.

Key Findings:
  • Achieved an average of 6.64 x 10^9 Vγ9Vδ2 T cells after 14 days of culture.
  • Low average vector copy number of 1.4 indicates safety and efficiency of the transduction protocol.
  • Demonstrated robust anti-tumor activity of CAR-γδ T cells in functional assays.
Interpretation:

The automated platform enables reproducible and compliant manufacturing of CAR-γδ T cells, highlighting their potential for clinical immunotherapy applications.

Limitations:
Conclusion:

The study presents a significant advancement in the large-scale production of CAR-γδ T cells for cancer immunotherapy.

Original Source(s)

A clinical-grade automated platform for the manufacturing of CAR-γδ T cells for immunotherapy

  • by Jan Kuska, Julia Kostyra, Lorraine Pinot, Evgeny Egorov, Nojan Jelveh, Lilian A. Martinez Carrera, Congcong Zhang, Svetlana Khorkova, Mario Assenmacher, Rimas Orentas, Sabine Mueller, José Villacorta Hidalgo

  • May 22, 2026

Related Content

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

Data requirements of an informative, directive, and preventive mobile health application for gastric cancer

Trametinib as second-line therapy for advanced KRAS G12C-mutant non-small cell lung cancer: a single-center clinical analysis of 20 cases